← Back to Search

Other

Methylene Blue Mouthwash for Oral Mucositis Pain

Phase 3
Recruiting
Led By Regina M Mackey, M.D.
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 3 days
Awards & highlights

Study Summary

This trial compares a new mouthwash to standard of care to treat oral pain from cancer-related mucositis. It may improve oral pain and provide a better treatment.

Who is the study for?
This trial is for cancer patients with severe mouth sores (Grade 3-4 oral mucositis) causing pain, who are currently hospitalized. Participants must have an active cancer diagnosis and be able to give informed consent.Check my eligibility
What is being tested?
The study is testing if methylene blue mouthwash can better manage pain from severe mouth sores in cancer patients compared to the standard care mouthwash typically used for this condition.See study design
What are the potential side effects?
Potential side effects of methylene blue mouthwash may include tooth staining, increased saliva production, a burning sensation or irritation in the mouth, and possible allergic reactions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 3 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 3 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in oral pain
Secondary outcome measures
Change in the amount of daily requirements of oral morphine equivalents
Change in the amount of oral intake

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Methylene Blue Mouthwash GroupExperimental Treatment1 Intervention
Patients receive Methylene Blue mouthwash as needed on study.
Group II: Standard of Care Mouthwash GroupActive Control1 Intervention
Patients receive standard of care mouthwash as needed on study.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for blood cancers include chemotherapy, radiation therapy, and supportive treatments like methylene blue mouthwash. Chemotherapy works by targeting rapidly dividing cancer cells, disrupting their growth and replication. Radiation therapy uses high-energy radiation to damage the DNA of cancer cells, leading to cell death. Methylene blue mouthwash, studied for its antiseptic and analgesic properties, helps manage oral mucositis pain, a common side effect of cancer treatments. These treatments are crucial for blood cancer patients as they directly target cancer cells and alleviate treatment-related complications, improving overall patient outcomes and quality of life.
Effect of two oral care protocols on the incidence of stomatitis in hematology patients.Oral cancer and mouthwash use: evaluation of the epidemiologic evidence.Indications for and referrals to oral care for cancer patients in a county hospital.

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,239 Previous Clinical Trials
3,771,539 Total Patients Enrolled
Regina M Mackey, M.D.Principal InvestigatorMayo Clinic in Rochester
Regina M MackeyPrincipal InvestigatorMayo Clinic in Rochester

Media Library

Methylene Blue Oral Rinse (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05878405 — Phase 3
Blood Cancers Research Study Groups: Standard of Care Mouthwash Group, Methylene Blue Mouthwash Group
Blood Cancers Clinical Trial 2023: Methylene Blue Oral Rinse Highlights & Side Effects. Trial Name: NCT05878405 — Phase 3
Methylene Blue Oral Rinse (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05878405 — Phase 3
~20 spots leftby Dec 2024